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Fry  2, Eva Morfeldt4, Outi Nyholm5, Assaf Rokney6, Merav Ron6, Lotta Siira5, Kevin J. Scott7, 
Andrew Smith7, Louise Thom7, Maija Toropainen5 & Didrik F. Vestrheim8
An external quality assessment (EQA) scheme for pneumococcal serotype identification has been 
performed over a period of 11 years, by a network of European pneumococcal reference laboratories. 
We report the results from the EQA, and present an assessment of the acceptability and utility of the 
EQA scheme. Reports from 22 EQA panels distributed in 2005–2016 were analysed. Each EQA panel 
consisted of seven isolates. A questionnaire including seven questions related to the acceptability 
and utility of the EQA scheme was distributed to all participating laboratories. Altogether, 154 
pneumococcal isolates were tested. Of the 92 serologically distinct serotypes currently defined, 49 
serotypes were included in the rounds. Discrepant results were observed in eight EQA rounds, involving 
11 isolates (7.1%, 95% CI: 4% to 12%). All participating laboratories reported that the EQA scheme 
was useful for quality assurance purposes. Our results show that comparable serotyping data can be 
obtained in different laboratories. The EQA participation helps to keep the typing procedures at a high 
standard and provides data for accreditation purposes. The EQA is helpful when new technologies are 
introduced, and reveal limitations of both genotypic and phenotypic methods. Continuation of the 
presented EQA scheme is planned.
Streptococcus pneumoniae (pneumococcal) infection is a cause of high morbidity and mortality among children 
and elderly worldwide, and one of the most frequent causes of bacteraemia and meningitis in infants globally1–3. 
It is essential to detect, identify and serotype S. pneumoniae correctly4,5 in order to provide reliable surveillance 
data to guide pneumococcal vaccination policies, and to evaluate the effect of national vaccination programs on 
pneumococcal serotype distribution6. Pneumococcal serotyping performed at national reference laboratories is 
an important part of Invasive Pneumococcal Disease (IPD) surveillance and pivotal for assessing the effective-
ness of pneumococcal immunisation programmes introduced in many countries during the last 17 years6,7. The 
impact of the immunisation programs on the epidemiology of pneumococcal disease globally can be assessed 
by compilation and comparison of pneumococcal serotype data from different countries and surveillance sites8. 
When comparing data between different reference laboratories, serotyping results have to be comparable for the 
different laboratories, irrespective of the procedures and serotyping methodologies used9,10.
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External quality assessment (EQA) schemes allow laboratories to assess their performance to identify and 
type a pathogen, even when different methodologies have been used11–13. The EQA results can also document 
that laboratory procedures at a certain time point are in accordance with internationally agreed procedures9,10,14.
Many methods have been described for serotyping of S. pneumoniae7,15. The methods can be divided into two 
major types of identification; phenotypic and genotypic7,12,15.
EQA schemes for pneumococcal serotyping can aid laboratories in performing correct capsular identification 
of S. pneumoniae, despite the use of different methodologies. We describe an international EQA scheme that 
has been performed semiannually over a period of 11 years, based on a collaborative network of pneumococcal 
reference laboratories. Results from the scheme were summarised in order to evaluate the performance of pneu-
mococcal reference laboratories using different serotyping procedures. We also assessed the acceptability and 
usefulness of the EQA scheme. Based on this evaluation, recommendations for setting up an EQA scheme were 
formulated.
Materials and Methods
Participants. The EQA scheme started in June 2005 with an agreement between the two reference labo-
ratories SHLMPRL and SSI. Currently, eight institutions from eight countries (Table 1) participate in the EQA 
distributions: 1. Scottish Haemophilus, Legionella, Meningococcus & Pneumococcus Reference Laboratory 
(SHLMPRL), Scotland; 2. Statens Serum Institut (SSI), Denmark; 3. Norwegian Institute of Public Health (NIPH), 
Norway; 4. National Institute for Health and Welfare (THL), Finland; 5. Public Health England (PHE), England. 
6. The Public Health Agency of Sweden (PHAS), Sweden; 7. Netherlands Reference Laboratory for Bacterial 
Meningitis (NRLBM), the Netherlands; and 8. National Reference Laboratory, Israel.
The names of several institutions have changed over the years; the most recent names and abbreviations have 
been used throughout the manuscript.
Bacterial isolates and dispatches. The EQA panels were prepared and shipped by the sending lab-
oratories selected on a rotating principle, in which all participating laboratories in turn became the “sending 
laboratory”.
Each EQA panel was shipped in compliance with international packaging and transportation requirements 
for infectious substances according to the International Air Transportation Association (IATA) Dangerous Goods 
Regulations UN3373 Category B (see http://www.iata.org). Each panel consisted of seven clinical S. pneumoniae 
isolates chosen by the sending laboratory. The isolates were sent blinded, but labelled with a unique panel number, 
in a suitable transportation medium and container at ambient temperature. The EQA results presented in this 
study are from EQA panels sent in the period from June 2005 to September 2016.
EQA panels. The pneumococcal isolates were serotyped by each laboratory, using their routine procedures 
for pneumococcal serotyping. After species identification and serotyping, the results were returned to the send-
ing laboratory by e-mail on completion of a submission form within 6 weeks. The receipt of both isolates and the 
results were confirmed by e-mail.
Concluding and reporting of EQA results. The combined results were reported back by the sending lab-
oratory to all participating reference laboratories. If all the results were in agreement, a final report was prepared 
by the sending laboratory after which the EQA round in question was concluded.
If discrepancies were found, this was reported to the laboratory sending the discrepant result and thereby giv-
ing the laboratory an opportunity to reanalyse the isolate or isolates in question after which the results were com-
pared again. If the results were in agreement, the procedure above was followed. If there were still discrepancies, 
the isolates in question were sent again from the sending laboratory to be reanalysed in both laboratories. Based 
on this test, the sending laboratory and the laboratory with the discrepancies discussed the results obtained and 
tried to agree on a consensus result, including the test results, on which the majority of the laboratories reached. If 
needed an external laboratory was contacted to perform additional serotyping. The choice of external laboratory 
depended on the distributing laboratory’s preference.
Year Institutions Comments
2005
Scottish Haemophilus, Legionella, Meningococcus & Pneumococcus 
Reference Laboratory (SHLMPRL) Scotland and Statens Serum Institut 
(SSI) Denmark
This EQA was performed based on a personal agreement 
between the two laboratories on May 23, 2005.
2009 SHLMPRL, Norwegian Institute of Public Health (NIPH) Norway, SSI Agreement of External Quality Assurance on serotyping of Streptococcus pneumoniae
2010 SHLMPRL, NIPH, SSI, National Institute for Health and Welfare (THL) Finland, Public Health England (PHE), England
Agreement of External Quality Assurance on serotyping of 
Streptococcus pneumoniae
2013 SHLMPRL, NIPH, SSI, THL, PHE Agreement of External Quality Assurance on serotyping of Streptococcus pneumoniae
2015 SHLMPRL, NIPH, SSI, THL, PHE, The Public Health Agency of Sweden (PHAS), Sweden.
Agreement of External Quality Assurance on serotyping of 
Streptococcus pneumoniae
2017
SHLMPRL, NIPH, SSI, THL, PHE, PHAS, Netherlands Reference 
Laboratory for Bacterial Meningitis (NRLBM), the Netherlands, 
National Reference Laboratory, Israel
Agreement underway including NRLBM and National 
Reference Laboratory Israel
Table 1. Year of signing agreement for EQA programs.
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Lessons learned from the analysis and reanalysis of discrepant results were documented in internal and 
shared reports between the participating laboratories and incorporated into routine practice as necessary and 
appropriate.
Ownership of the isolates used in the EQA. Because the EQA scheme involves an international 
exchange of clinical isolates, in the EQA agreement the ownership of the collection is also described. All isolates 
remain the property of the province, state or country from which they were distributed. Isolates that are used in 
EQA panels may be retained by the participating laboratories for internal reference use, but the recipients may not 
share them with any other laboratory, nor use them for their own research purposes without the written consent 
of the laboratory from which they were distributed.
Methods used by the EQA members. The methods used by the participating laboratories were mainly 
phenotypic tests although genotypic capsular typing was also used (Table 2). A general overview of the tests 
can be found described in previous literature7,15,16. The specific tests used by each participating laboratory are 
described in Table 2.
NIPH. Isolates were incubated on blood agar plates and serotyped by Quellung reaction using type-specific 
pneumococcal rabbit-antisera (SSI Diagnostica, Denmark). Optochin susceptibility and bile solubility tests were 
used for species identification, if necessary.
SSI. Latex and Quellung. The pneumococci were identified by optochin susceptibility and bile solubility tests. 
All isolates were serotyped either by Quellung reaction alone or by the Pneumotest Latex kit (SSI Diagnostica, 
Denmark) combined with the Quellung reaction using type-specific pneumococcal rabbit-antisera as previously 
described (SSI Diagnostica, Denmark)17.
Latex agglutination test (ImmuLex™ Pneumotest kit, SSI Diagnostica, Denmark). For determination of sero-
group, the latex agglutination test was performed by using the ImmuLex™ test as described by the packaging 
inserts (SSI Diagnostica, Denmark). Briefly, isolates were cultured for 24 hours in Todd Hewitt broth (TH-broth, 
SSI Diagnostica, Denmark). Ten microlitres from this culture was mixed with specific antisera for observation of 
agglutination reactions.
The capsular reaction test (Quellung test). For full serotyping, isolates were serotyped/confirmed by Quellung 
reaction alone (SSI Diagnostica, Denmark) combined with the Quellung reaction using type-specific pneumo-
coccal rabbit-antisera as previously described (SSI Diagnostica, Denmark)17.
PHE 1. From 2005–2010, isolates were grown on Columbia Blood Agar, a 1 µl loop of culture was used to inoc-
ulate a 2% deoxycholate solution in a PCR plate, this solution was then further diluted in PBS to a final dilution of 
~1:2000 before being run in a Luminex antigen-capture assay using serotype specific monoclonal antibodies for 
serotypes 1, 3, 4, 5, 6 A/C, 6B, 7 F/A, 8, 9 V, 14, group 18, 19 A, 19 F and 23 F18. Any isolate not giving a definitive 
result in the assay was serotyped or subtyped using slide agglutination. After 2010 only the following slide agglu-
tination method was performed due to the serotypes available in the Luminex assay becoming considerably less 
frequent in the population.
Isolates were grown for four hours or overnight in 5 ml MAST Todd Hewitt broth (PHE media services) at 
35 °C with 5% CO2, centrifuged at 453xg for 30 min, and the supernatant removed, the cell pellet re-suspended 
in a small residual volume of broth and subjected to slide agglutination tests with latex antisera (ImmuLex™ 
Pneumotest kit) or standard factor sera (SSI Diagnostica, Denmark).
EQA Laboratory name Method used
2005–2016B SHLMPRL Slide-agglutination using both Latex and standard type and factor antisera.
2005–2016B SSI Pneumotest Latex+Quellung reaction
2007A-2016B NIPH Quellung reaction for serotype identification using pool, group, type and factor sera.
2009A-2010B PHE 1
Luminex antigen detection assay for serotypes 1, 3, 4, 5, 6A/C, 7F/A, 8, 9V, 14, Group 18, 19A, 19F 
and 23F with Slide agglutination for typing or subtyping if necessary, using standard type and factor 
antisera.
2011A-2016B PHE 1 Slide agglutination both with Latex agglutination antisera and standard type and factor antisera
2014A- 2016B PHE 2 Whole Genome Sequencing (WGS) + bioinformatic script was introduced as secondary method for testing and evaluation of the procedure.
2009A-2016B THL Primarily multiplex PCR modified from a protocol by the Centers for Disease Control and Prevention (CDC), if needed Quellung was used for further serotyping.
2015B-2016B PHAS Gel diffusion, Latex kit, and the Quellung reaction
2016-B National Reference Lab. Israel
Capsular Sequence Typing (CST) PCR identification of all types. Quellung reaction for serotype 
identification using pool, group, type and factor sera.
2016-B NRLBM Type: Slide-agglutination, Subtype: Quellung reaction, Multi-Locus Sequence Typing (MLST): PCR-sequencing
Table 2. Methods used by each participating EQA member.
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PHE 2. From 2014 whole genome sequencing was introduced into the laboratory and an additional set of 
results was included with the phenotypic results while the technology was being developed for incorporation into 
routine use.
DNA extraction, whole genome sequencing and bioinformatic analysis for serotype determination was per-
formed as described by Kapatai et al.16.
SHLMPRL. Organisms were grown anaerobically on Columbia horse blood agar (Oxoid™) for 24 h. Slide 
agglutination was performed using Pansorbin cells absorbed with type specific pneumococcal anti-sera obtained 
from the Statens Serum Institute19.
THL. The pneumococci were identified by the optochin susceptibility test, and if the result was inconclusive 
with the bile solubility test. Six sequential multiplex PCRs (mPCRs) were used for the deduction of serotypes. 
Quellung reaction was used to distinguish co-detected serotypes, for subtyping, and for serotyping if no serotype- 
or group-specific product was obtained in any of the sequential mPCRs20. The antisera for Quellung reaction were 
obtained from SSI Diagnostica, Denmark, and used according to the manufacturer’s recommendation.
PHAS. The isolates were identified by the optochin susceptibility test, and if needed with the bile solubility 
test. All isolates were serotyped by gel diffusion using type specific pneumococcal anti-sera (SSI Diagnostica, 
Denmark), and some in addition by the Quellung reaction.
NRLBM. The pneumococci were identified by optochin susceptibility. All isolates were serotyped by the Latex 
agglutination test (ImmuLex™ Pneumotest kit, SSI Diagnostica, Denmark combined with the Quellung reaction 
using type-specific pneumococcal rabbit-antisera as previously described (SSI Diagnostica, Denmark)17.
National Reference Laboratory Israel. The isolates were grown on sheep blood agar for 18–24 h at 35 °C 
with 5% CO2. All isolates were typed in parallel by CST typing21, and Quellung (Neufeld antisera, SSI Diagnostica, 
Denmark). CST PCR sequences were analyzed on the BioNumerics 7.1 platform (Applied Maths) and compared 
with the global database. In case of discrepant results between the two methods, the Quellung result was reported.
Questionnaire on Acceptability and Usefulness. In November 2016, a questionnaire regarding the 
acceptability and usefulness of participating in the EQA distributions was sent to all eight laboratories. The fol-
lowing questions were included in the questionnaire: 1. Is the frequency of EQA acceptable, or is it too frequent? 
2. Is the workload for preparing and shipping panels acceptable? What is the limit? 3. Are the results useful to 
improve and maintain the performance of the laboratory? 4. Is the EQA useful for quality assurance purposes? 5. 
Is your laboratory accredited? If yes, what method or process is accredited, and according to which standard? 6. 
Is the EQA useful for accreditation purposes? 7. What could be changed or added?
Results
For description and definition of different typing sera systems used, see the inserts from the producer (SSI 
Diagnostica, Denmark, www.ssidiagnostica.dk).
EQA results. From June 2005 to September 2016, 22 EQA panels were distributed, each consisting of seven 
clinical pneumococcal isolates, i.e. including a total of 154 pneumococcal isolates. Panels were distributed twice a 
year, except for 2005 and 2006 when only one EQA panel was shipped; 2005A and 2006A, respectively (Table 3).
Overall, 49 distinct serotypes were included in the 22 panels (Fig. 1). All pneumococcal conjugate vaccine 
(PCV) serotypes, and all but one (serotype 2) pneumococcal polysaccharide vaccine (PPV) serotypes were 
included. Fully concordant serotyping results were observed for 14 EQA panels. Of the 154 isolates tested, 26 
(17%) belonged to serotypes included in the 7-valent PCV, 36 isolates (23%) belonged to serotypes included in 
the 10-valent PCV, and 50 isolates (32%) belonged to serotypes included in the 13-valent PCV (Fig. 1). Serotype 
22 F was most often included in the test panel, followed by 23B, 19 A, 9 N and 23 A. Around 40 pneumococcal 
serotypes were not included in any of the test panels. Combining all the tested isolates (n = 154), a discrepancy 
was found with 11 isolates (7.1%, 95% CI: 4% to 12%) at first test, and the discrepancy was not resolved in four 
distinct isolates (2.6%, 95% CI: 1% to 7%). The EQA panels showing a disagreement in the typing results are 
presented below.
The EQA 2005-A. One laboratory found the 17 F isolate as a non-typeable isolate. However after retesting 
the isolate, it was found to be a 17 F isolate. The laboratory was not able to find the reason for the typing error in 
first test. This explanation was noted and accepted.
The EQA 2009-B. EQA 2009-B showed a disagreement between the reference laboratories because one lab-
oratory did not go further than the group level in serotype identification and did not determine the specific sero-
types using factor sera. This limitation was noted and accepted.
The EQA 2010-A. The first test showed a disagreement with the isolate 35B, however after retesting all labo-
ratories agreed on the typing results of the isolate as 35B.
There was also a disagreement with isolate 12 F, with one laboratory serotyping this isolate as a 12B. The lab-
oratory with the disagreement retyped the isolate several times, but was not able to confirm serotype 12 F. The 
laboratory changed the batch of its factor antisera but were however still not able to provide an explanation for the 
discrepancy. In 2017 the laboratory retested the isolate; both with phenotypic testing and molecular identifica-
tion, and this time they were able to confirm the serotype of the isolate as 12 F. It was speculated that the original 
www.nature.com/scientificreports/
5SCIENTIFIC REPORTS | 7: 13280  | DOI:10.1038/s41598-017-13605-8
problem with the identification was due to difficulties with interpreting the agglutination reaction. The majority 
of other laboratories used the same lot of the 12 factor antisera.
The EQA 2012-A. EQA 2012-A showed a preliminary disagreement for a serotype 9 V isolate, which by one 
laboratory was identified as a serotype 9 A, however after retesting the isolate at the laboratory, they agreed on 
serotype 9 V. The typing problem was referred to the problematic reading of a positive reaction of factor sera 9 g. 
This explanation was noted and accepted.
The EQA 2012-B. EQA 2012-B showed a disagreement between the reference laboratories of identifying a 
serotype 15 C, which was serotyped as 15B by one reference laboratory. The consensus result was 15 C. However, 
laboratories did report that cross-reactions sometimes did occur with the group 15 factor sera and differentiation 
between 15B and 15 C was proven quite difficult. The reference laboratory identifying the 15B, found that with 
individual factor sera interpretations in Quellung, the reactions with factor sera 15b and 15e were positive, 15c 
was negative, and 15 h was interpreted as a weak positive possible cross-reaction (SSI Diagnostica, Denmark, 
insert for factor sera). At the time, it was described that serotypes 15B and 15 C may interconvert through a 
reversible event, which was one explanation for why the antisera reactions were not straightforward to inter-
pret. The explanation was based on published data on serotype 15B versus 15 C22–24. One laboratory noted that 
they had experience in identifying both 15B and 15 C from one culture/plate due to different morphologies, 
and to identify the two types from the same cultures on repeated typing following freezing. They had however 
not observed problems with cross-reactions of factor sera, and the reactions were usually easy to interpret. The 
laboratory reports 15B and 15 C as distinct serotypes in their internal laboratory reports, but for surveillance 
reports they usually combine 15B/C as a group. Discrepancies between 15C and 15B were also reported in for the 
Circumpolar pneumococcal EQA10.
For serotype 10 A and 16 F in the panel, one laboratory did not type further than to group level, therefore the 
identification result was group 10 and 16.
The EQA 2014-B. EQA 2014-B showed a disagreement between the reference laboratories on a serotype 29 
versus 35B isolate. The organizing laboratory determined it as type 29 while three other laboratories found it as 
type 35B. One laboratory could not differentiate between serotype 29 or 35.
The organizing laboratory found a reaction in pool G and for 29, 35 and 42. When using the factor-sera fol-
lowing reactions were observed: 35a (negative), 35b (negative), 35c (+++), 29b (+++), 42 (negative). Due to the 
missing reaction with factor-sera 35a, the isolate was not of type 35 but rather 29. One laboratory identified the 
serotype 35B directly through a multiplex PCR (mPCR) instead of using the Quellung. The primers used in the 
mPCR amplify the wcrH locus25. Aligning these primers with the serotype 29 reference sequence S. pneumoniae 
isolate 34373 (serotype 29) CR931694 did not show significant similarity, and there had not been any previous 
reports about discrepancy between mPCR and Quellung results for serotype 35B isolates.
Another laboratory concluded that it was serotype 35B, based on reactions in 35b, 35c, 29b, and 42a, as well as 
29 and 35. The laboratory did not use the 35a serum; however, after retesting with 35a, they still interpreted the 
reactions as ambiguous. The packet insert (SSI Diagnostica, Denmark) stated a possible cross-reaction between 
type 29 and 35B. Although a reaction in 35a is needed for serotype 35B, it is not evident from the packet insert 
that a negative reaction in 35a is used to identify serotype 29. The laboratory also performed CST-typing (wzh 
gene sequencing)21. The result, with 100% match, indicated capsule type 15C-01, with corresponding serotypes 
17 A, 35B and 35 C. There was no mention of serotype 29. This result was confirmed by another participating 
laboratory.
In conclusion the isolate was found to genetically resemble a serotype 35B, however it was concluded that 
phenotypically it was a serotype 29. The isolate was tested by SSI Diagnostica (Denmark), the company producing 
the typing sera, and they confirm it to be phenotypically serotype 29. Discrepancies between serotype 29 and 35B 
have been reported by the Circumpolar EQA as well10. In this study the discrepancy was explained by the pres-
ence of reaction with factor serum 29b in the antigenic formula of both serotypes.
The EQA 2016-A. EQA 2016-A showed a disagreement between the reference laboratories for two isolates 
(serotype 19 F and 40).
Serotype 19 F isolate: All results were concordant by conventional phenotypic methods, although one labo-
ratory found that the isolate provided a strong reaction with 19b latex sera but also some reaction with 19c latex 
sera. With WGS the isolate identified as genotype 19 A by the current WGS pipeline, however it appeared to have 
an unusual sequence properties. Another laboratory mentioned that serotype 19 F isolate only produced the 
internal control band in the mPCR and was serotyped through Quellung.
Regarding the serotype 40 isolate, one laboratory found the identification challenging. The isolate did not 
react in the group-7 serum, but did react with the factor-serum. A second laboratory found that the serotype 40 
isolate caused some problems as it reacted ambiguously. Even the bile-solubility test was inconclusive. It provided 
a weak response in the latex pool C and could possibly be a serotype 24, but this was not a definitive result. A 
third laboratory mentioned that the isolate showed a reaction with pool C but further typing was not possible due 
to auto-agglutination. The laboratory mentioned that the isolate failed the WGS serotyping pipeline with CPS 
operon coverage to nearest serotype just under the 90% cut-off. It was most similar to 7B, 7 C, 40. It also had a new 
MLST type ST11674, due to a novel spi allele. One of the laboratories mentioned that the serotype 40 isolate was 
mPCR positive for wzg (=cpsA, internal positive control) and produced an amplicon that co-detects serotypes 
7 C, 7B, and 40 through the wcwL gene. To distinguish co-detected serotypes the Quellung reaction was used. 
The reaction for group 7 serum was negative and serotype 40 serum was positive, thus the laboratory result was 
serotype 40. The isolate also reacts positively with factor serum 7 f.
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Acceptability and usefulness of the EQA. The questionnaire results showed that all laboratories found 
that the distribution frequency of two EQA panels a year was acceptable (Question 1), although one laboratory 
mentioned that one EQA panel a year would be sufficient. Another laboratory stated that more than two EQA 
panels a year would be too many. In general the workload for preparing and shipping seven isolates to eight 
laboratories (question 2) was found acceptable, although it was stated by several laboratories that it was close to 
the limit. One laboratory mentioned the possibility of using an external provider to supply the test samples as an 
alternative to the laboratories doing it themselves and thereby possibly increase efficiency and reduce the cost. 
Three laboratories had not yet performed the task of sending the test panels.
All laboratories found that the EQA results (Question 3) were useful for improving and maintaining the per-
formance of the laboratory. Several laboratories found that, using the results, they were able to improve their 
identification procedure. It was mentioned by one laboratory, that some panel results generated an interesting 
discussion regarding comparison and the use of different typing methods particularly between genetic and phe-
notypic methods.
All laboratories agreed that the EQA was useful for their quality assurance (Question 4). For seven laboratories 
the pneumococcal serotyping is accredited (Question 5), while one laboratory is in the process of obtaining an 
accreditation. For three laboratories the accreditation was specific for the serotyping of pneumococcal isolates. 
The standards included SWEDAC ISO17025, NS-EN ISO/IEC17025, DANAK ISO17025, UKAS ISO15189:2012, 
SFS-EN ISO/IEC17025:2005, ISO1518, ISO15189.
EQA
Number of participating 
laboratories
Tested serotype and number of correct identification Serotype (Number 
of correct identifications). Discrepant results which did not reach a final 




Final comments to EQA 
results. For details see results 
section.
2005-A 2 (SHLMPRL*, SSI) 9N (2) 23F (2) 17F (2) 23A (2) 1 (2) 22F (2) 18C (2) Yes
First result from one lab showed 
a rough isolate instead of 17F. 
Retesting showed correct results.
2006-A 2 (SHLMPRL, SSI*) 23A (2) 19A (2) 14 (2) 3 (2) 38 (2) 31 (2) 15B (2) Yes
2007-A 3 (NIPH, SHLMPRL*, SSI) 11A (3) 4 (3) 18C (3) 6B (3) 7F (3) 9V (3) 27 (3) Yes
2007-B 3 (NIPH, SHLMPRL, SSI*) 33F (3) 24F (3) 11A (3) 22F (3) 37 (3) 19A (3) 15A (3) Yes
2008-A 3 (NIPH, SHLMPRL, SSI*,) 21 (3) 14 (3) 10A (3) 33F (3) 19F (3) 1 (3) 22F (3) Yes
2008-B 3 (NIPH, SHLMPRL*, SSI) 22F (3) 16F (3) 8 (3) 7F (3) 5 (3) 13 (3) 6A (3) Yes
2009-A 5 (NIPH, PHE, SHLMPRL, SSI*, THL) 15B (5) 9A (5) 23A (5) 16F (5) 38 (5) 4 (5) 9N (5) Yes
2009-B 4 (NIPH
*, PHE, SHLMPRL, 
SSI) 19F (4) 35F (4) 6C (4) 6A (4) 33A (4) 24F (4) 15B (4) Yes
One lab did not distinguish 
between 6A and 6C
2010-A 5 (NIPH, PHE, SHLMPRL
*, 
SSI, THL) 31 (5) 35B (5)
12F (4) 
12B (1) 17F (5) 6B (5) 23B (5) 19A (5) No
One laboratory had to 
retest the isolate before 
correct identification of 35B. 
Disagreement with 12 F/12B.
2010-B 5 (NIPH, PHE, SHLMPRL, SSI*, THL) 3 (5) 20 (5) 37 (5) 4 (5) 22F (5) 15A (5) 7F (5) Yes
2011-A 5 (NIPH, PHE, SHLMPRL, SSI, THL*) 7B (5) 1 (5) 6A (5) 8 (5) 34 (5) 11A (5) 14 (5) Yes
2011-B 5 (NIPH, PHE
*, SHLMPRL, 
SSI, THL) 1 (5) 8 (5) 23B (5) 12F (5) 4 (5) 6C (5) 35B (5) Yes
2012-A 5 (NIPH
*, PHE, SHLMPRL, 
SSI, THL) 9V (5) 19A (5) 23B (5) 6B (5) 7C (5) 19F (5) 7F (5) Yes
1 lab had a problem with 9 g 
factor serum for 9 V. Retested 
and found correct serotype.
2012-B 5 (NIPH, PHE, SHLMPRL
*, 
SSI, THL) 15A (5) 10A (5) 16F (5) 37 (5) 19A (5) 14 (5)
15C (4) 
15B (1) No
See detailed explanation in 
results section
2013-A 5 (NIPH
*, PHE, SHLMPRL, 
SSI, THL) 6B (5) 23A (5) 23B (5) 8 (5) 19F (5) 20 (5) 9N (5) Yes
2013-B 5 (NIPH, PHE, SHLMPRL, SSI, THL*) 6C (5) 22F (5) 3 (5) 18C (5) 9V (5) 11A (5) 35F (5) Yes
2014-A 5 (NIPH, PHE
*, SHLMPRL, 
SSI, THL) 8 (5) 24F (5) 12F (5) 23B (5) 19A (5) 23A (5) 9N (5) Yes
2014-B 5 (NIPH, PHE, SHLMPRL, SSI*, THL) 9A (5) 11B (5) 37 (5) 31 (5)
29 35B 
(3) (2) 15B (5) 10B (5) No
See explanation for 
disagreement in results.
2015-A 5 (NIPH, PHE, SHLMPRL
*, 
SSI, THL) 21 (5) 9N (5) 3 (5) 16F (5) 22F (5) 23B (5) 7F (5) Yes
2015-A 6 (PHAS, NIPH
*, PHE, 
SHLMPRL, SSI, THL) 10B (6) 15A (6) 6C (6) 9V (6) 23F (6) 24F (6) 17F (6) Yes
2016-A 6 (PHAS, NIPH
*, 2xPHE, 
SHLMPRL, SSI, THL) 19F (6)
40 (2) 
NT (4) 6D (7) 20 (7) 15B (6) 23B (7) 9N (7) No
See explanation for 
disagreement in results.
2016-B
8 (PHAS, National Reference 
Lab. Israel, NRLBM, NIPH, 
PHE*, SHLMPRL, SSI, THL)
33F (8) 25A (8) 10A (8) 3 (8 22F (8) 23A (8) 16F (8) Yes
No factor sera available for 
serotype 25, were only able to 
identify to group level.
Table 3. EQA typing results from 2006–2016. *Organizing laboratory.
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All laboratories found that the EQA was useful for their accreditation. One laboratory was in the process of 
obtaining their accreditation, and would use the EQA for this purpose (Question 6). One laboratory mentioned 
that they used a separate EQA as part of their accreditation.
Several changes to the EQA scheme were suggested (Question 7): to include molecular characterisation to 
present predicted serotype or the MLST type, to share the laboratory test protocols to enable standardisation of 
all identification protocols in the participating laboratories, and to add more isolates to the panel to cover more 
of the serotypes they received.
Discussion
The purpose of an EQA is to compare the results and interpretations of laboratory analyses. This serves as a qual-
ity assurance for the participating laboratory, provision of early warning for systematic problems associated with 
kits or operations; provision of objective evidence of testing quality; indication of areas that require improvement 
and to identify training needs, and to improve comparability and harmonized reporting between laboratories 
despite the use of different laboratory methods. EQAs are used in many different settings11,13,26 both to provide 
a quality statement9,10,26, but also to help guide the reference laboratories in providing the appropriate labora-
tory tests9,10,12. This paper describes an EQA scheme for S. pneumoniae serotype identification arranged between 
national reference laboratories that started in June 2005 and is still on-going. The EQA demonstrate a high con-
cordance of serotype results between the participating laboratories, although different serotype identification 
methods are used. Other pneumococcal EQA studies with different setup, test interval and number of isolates 
have been presented although with variable results regarding the concordance of serotype results9,10,14.
The typing procedures used at the participating laboratories were different (Table 2), although the Quellung 
test (six laboratories) and slide agglutination test (three laboratories) were used as the final serotype identification 
procedure most of the laboratories (Table 2). The majority of the typing discrepancies were due to inability to 
serotype further than the group level, or problems with interpretation of the reactions when using factor sera. In 
general we found that although different identification procedures were used between the laboratories, the dis-
crepancies were few (Fig. 1). Of the 154 isolates tested over the years, only a 7.1% discrepancy was observed after 
the initial testing, and after the final testing this rate declined to 2.6%. This level of discrepancy is similar to the 
around 5% observed in other pneumococcal studies on validation of laboratories pneumococcal serotyping9,10,14. 
However, a few isolates did provide typing disagreements, which were at the time not possible to resolve satisfac-
torily. During the study period, four isolates did not reach a final identification agreement between all participant 
laboratories (Table 3). Discrepancies with no satisfactory solution have also been observed by Reasonover et al.10, 
in which they reported 4 isolates with no final agreement on the typing result. Reasonover et al.10 also found 
problems with the identification of group 15 isolates and between serogroup 29 and serotype 35B, as also seen in 
this study. Also other EQA programs describe discrepancies for which there were no explanations to be found10,14.
One laboratory has started to include WGS of pneumococcal isolates, however the use of WGS and other 
molecular based methods compared to phenotypic methods does highlight potential differences, which need to 
be discussed before molecular methods can replace phenotypic methods. The laboratory using the WGS method 
has tried to match the phenotypic methods as far as possible. However genotypic methods may sometimes pick 
up new genotypes, which may only later be described phenotypically or may indeed correspond to existing phe-
notypic serotypes despite being genetically different16. Therefore a discrepancy may not be a mistake but rather 
a new variant and it will take more time to investigate such issues, e.g. the 29/35B discrepancy observed in EQA 
2014-B16. Using phenotypic methods versus molecular methods will therefore give disagreements between refer-
ence laboratories, particular with regards to the number of isolates defined as non-typeable. These are problems 
that are also seen by other groups working with pneumococcal typing methods7,16.
Figure 1. Serotypes included in the EQA, and the frequency of the tested isolates. The black bars below the 
X-axis present the serotypes included in the three different conjugated vaccines.
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Because many laboratories perform their pneumococcal identification scheme in relation to monitoring the 
effect of introduced pneumococcal vaccines6,7,27, it is essential to provide an accurate serotype identification. It is 
therefore important to find a procedure in the future that incorporates the benefit from both capsular gene-based 
typing and capsular phenotyping. One possible future identification protocol could be the protocol presented 
by Kapatai et al.16 where a WGS method is used for capsular genotyping, and based on the WGS results from a 
specific isolate additional phenotypic tests are performed if necessary. For example when a molecular serotype is 
not obtained, or when the appearance of colonies indicates a lack of capsule production (rough/small appearance 
on culture plates). Another study has also suggested the use of molecular methods for screening followed by 
phenotypic methods for examinations28. Including WGS in the identification procedure will also provide easy 
determination of the MLST type and presence of resistance genes15. Because there are still unsolved differences 
between capsular gene based methods and capsular phenotyping methods16,28, EQAs will probably experience 
a higher number of discrepancies if EQA programmes involve laboratories using a mixture of these methods, 
compared to an EQA involving only laboratories using phenotypic methods. It is therefore not yet recommended 
to directly compare the outcome from these two typing procedures in an EQA.
In this study, we have only presented data based on serotyping of confirmed pneumococcal isolates. However, 
a growing problem for many microbiological laboratories is the separation of S. pneumoniae from other species 
within the viridans group29. For example a method such as optochin susceptibility has recently been recom-
mended not to be used for confirming S. pneumoniae due to increasing number of optochin resistance pneumo-
coccal isolates30. It is therefore essential that isolates used in an EQA are properly identified as S. pneumoniae.
Serotyping of pneumococci is performed by accredited methods in seven of the eight participating refer-
ence laboratories. Responses to the questionnaire on acceptability and utility indicated that the EQA scheme is 
important for continuous quality assurance and improvement, and for achieving and maintaining accreditation 
of laboratory procedures. The EQA scheme is run by collaboration between laboratories, and does not receive 
specific funding. Although this is currently described as acceptable by the participants, an increased work-load by 
including more laboratories, or additional laboratory procedures, might tip this into unacceptable.
Lessons learnt from this EQA since 2005 can be formulated into good advice for laboratories that are planning 
to set up an EQA, as listed below:
 1. Prepare an EQA contract describing the agreement between the laboratories, including the ownership of 
the isolates. In the described EQA all participants have signed an EQA contract. By preparing an EQA con-
tract, describing in detail what is required from each participant will ensure that all participants know what 
to expect when discrepancies are found and discussed. Because this EQA is dependent on participants in 
turn distributing seven clinical isolates from their own collection, it is important that the participants are 
aware of the limitations for use of the isolates, according to the contract.
 2. Each participant/prospective participant laboratory need to ensure the customs laws in a proposed partic-
ipant country allow for shipment of live microorganisms. At one time a laboratory tried to participate in 
this EQA, but had to leave it because their national customs laws would not allow the import of the isolates.
 3. Although relatively inexpensive, some cost has to be expected when participating in an EQA. In this EQA 
there are particular costs associated with being the panel sending laboratory for staff time, materials and 
shipping of the seven isolates to the other participants, although this task changes hands each time. Also, 
a cost has to be expected for the simple procedure of identification of the seven isolates, particularly if dis-
crepancies are found and repeats are necessary. In this EQA everything is based on voluntary participation 
under guidelines from a signed contract (rules). However it also has to be considered that there are private 
companies e.g., UKNEQAS (www.ukneqas.org.uk) that provide services within this field. Cost/benefit 
therefore has to be considered when choosing to participate in an EQA.
 4. Consideration should be made as to the maximum number of participating laboratories. In this EQA, it 
was found that the limitation of participants is around eight to ten laboratories before it will become too 
labour intensive due to the large number of replicates of isolates to be prepared for sending.
 5. Agree on the type and number of isolates that are to be included in the EQA. In this EQA we use every day 
clinical isolates that the administrating laboratory choose. Seven isolates are close to the maximum as this 
means that a minimum of 56 isolate slopes (and usually several extra as spares) need to be prepared for 
eight participating laboratories. In this EQA, it is the distributing participant that decides the serotypes of 
isolates to be sent. Again here it is important to evaluate what the needs for a participant are. If it is quality 
assurance of routine test procedures for common clinical isolates, then this EQA will be suitable. Howev-
er, if it is identification procedures for other purposes, such as developing new methods, then it has to be 
considered if another type of EQA is needed, where for example more specific or rare isolates are included.
 6. Consider how often the EQA should be performed each year. We have found that two EQAs a year is a 
good compromise between practicality and regularity. Some laboratories mentioned that one EQA a year 
would be enough for them to cover their needs. More than two EQA rounds a year is too many.
Conclusion
For the laboratories participating in the EQA the general conclusion is that the EQA participation helps the indi-
vidual laboratory to keep their typing procedures at a high standard, ensuring that the output can be compared to 
the pneumococcal typing output of other countries, and where appropriate, highlighting when adjustments and 
improvements are needed. It furthermore shows that pneumococcal typing data presented from the participating 
laboratories can be compared in surveillance studies, with the assurance that the different typing procedures 
used in the different countries provide a consistent output, and therefore should not introduce a bias factor to 
be considered when interpreting the data. The EQA is also helpful when introducing new technologies, adding 
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validation data and also showing limitations of both genotypic and phenotypic methods that need to be taken 
into account when interpreting data that is obtained from both methods. Continuation of the presented EQA 
program is scheduled.
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